Shire’s lanadelumab and SHP647 meet endpoints in respective trials
Irish pharmaceutical company Shire has reported positive topline results from its Phase III HELP clinical trial of lanadelumab to treat hereditary angioedema (HAE) and from the Phase II TURANDOT trial of SHP647 (PF-00547659) for the treatment of ulcerative colitis.
Albireo to initiate A4250’s Phase III clinical programme to treat PFIC
Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).
Majority of UC Cases Considered Mild to Moderate
Publication Date: Month 2017
Ulcerative colitis (UC) can be a significant cause of morbidity and worsen the quality of life for individuals with the disease, especially in its most severe form. In UC, the symptoms vary depending on the severity and can include urgent, persistent diarrhea, along with cramping and abdominal pain. Fortunately, in most UC patients, the disease is considered to be mild to moderate, which is associated with milder disease symptoms and improved treatment outcomes compared to severe forms of UC. Figure 1 presents the number of incident cases of UC in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), in 2015, by severity class.
Myovant reports positive data from Phase II trial of relugolix in Japan for endometriosis
Myovant Sciences has reported positive results from the Phase II clinical trial of relugolix in Japan to treat pain associated with endometriosis in women.